Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Monitoring Guidelines for Conventional Synthetic DMARDs
Description
The presentation discusses monitoring guidelines for conventional synthetic DMARDs, focusing on methotrexate (MTX), azathioprine, and mycophenolate. Methotrexate functions by inhibiting dihydrofolate reductase, impacting DNA production and proliferation, and poses risks of myelosuppression, infections, and hepatotoxicity, with monitoring recommendations including baseline complete blood counts, chemistry panels, and hepatitis screenings. The presentation highlights emerging data suggesting MTX does not independently cause chronic liver disease, though it may exacerbate existing conditions. The Fib4 score is introduced as a tool for assessing liver fibrosis risk in MTX users. Azathioprine's metabolism can lead to severe myelosuppression and other complications, which can be preemptively managed by checking TPMT levels. Similarly, mycophenolate may cause hematological toxicity and necessitates careful monitoring for drug interactions. The emphasis throughout is on the importance of regular monitoring and tailored management to mitigate risks associated with these medications.
View moreConclusions
- Methotrexate, Azathioprine, and Mycophenolate have well-established clinical efficacy but are associated with serious potential side effects that require careful monitoring.
- Methotrexate can lead to myelosuppression, hepatotoxicity, and has recently been called into question regarding its role in causing long-term liver fibrosis.
- Emerging evidence suggests that methotrexate alone does not cause liver fibrosis but could exacerbate existing conditions such as metabolic dysfunction or alcoholic liver disease.
- Routine baseline monitoring for patients on methotrexate should include a complete blood count, liver function tests, and screening for hepatitis and tuberculosis.
- For ongoing methotrexate therapy, patients require monthly blood tests for the first three months, followed by every three months thereafter, alongside periodic liver fibrosis risk assessments using the FIB-4 index.
- Azathioprine is associated with myelosuppression and hepatotoxicity; TPMT enzyme levels should be assessed before initiating treatment.
- Mycophenolate can cause hematological toxicity, particularly leukopenia, and requires ongoing monitoring of blood counts and liver function tests similar to azathioprine.
- Patients at high risk for myelosuppression from azathioprine or methotrexate should be started on a lower dose with close monitoring.
- Non-invasive tests and referrals to hepatology should be considered for patients showing signs of liver disease or fibrosis risk.
- Di Martino V et al. Nat Rev Rheumatol. Feb 2023
- Kanwal et al. Hepatology. May 2024
- Menter et al. JAAD. June 2020
- Zakerska-Banaszak et al. Toxics. 2022 10 (4)
- Terrault et al. Hepatology. 2018 67 (4)
- Perrillo et al. Gastroenterology. 2015 148
- Edmond Atallah, Jane I. Grove, Colin Crooks, ..., Richard J. Aspinall, Ruth Murphy, Guruprasad P. Aithal. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology.
- Busting the myth of methotrexate chronic hepatotoxicity. Editorial. Methotrexate-induced liver fibrosis: The end of a long-held belief. Vincent Di Martino.